Neurocrine Biosciences
NBIX
NBIX
417 hedge funds and large institutions have $9.23B invested in Neurocrine Biosciences in 2021 Q1 according to their latest regulatory filings, with 77 funds opening new positions, 160 increasing their positions, 126 reducing their positions, and 60 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
5.46% more ownership
Funds ownership: 95.8% → 101.27% (+5.5%)
3% more funds holding
Funds holding: 403 → 417 (+14)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Holders
417
Holding in Top 10
5
Calls
$69.4M
Puts
$52.1M
Top Buyers
| 1 | +$388M | |
| 2 | +$103M | |
| 3 | +$76.8M | |
| 4 |
Bank of New York Mellon
New York
|
+$74M |
| 5 |
DM
Deerfield Management
New York
|
+$70.5M |
Top Sellers
| 1 | -$179M | |
| 2 | -$122M | |
| 3 | -$93.1M | |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$54.5M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$48.5M |